Patents Examined by Kristin A Vajda
  • Patent number: 11912689
    Abstract: A method for producing an aromatic dianhydride includes reacting an aromatic diimide with a substituted or unsubstituted phthalic anhydride in an aqueous medium in the presence of an amine exchange catalyst to provide an aqueous reaction mixture including an N-substituted phthalimide, an aromatic tetraacid salt, and at least one of an aromatic triacid salt and an aromatic imide diacid salt. The method further includes removing the phthalimide from the aqueous reaction mixture by extracting the aqueous reaction mixture with an organic solvent using a single packed extraction column. The aromatic tetraacid salt is converted to the corresponding aromatic dianhydride. Aromatic dianhydrides prepared according to the method are also described.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: February 27, 2024
    Assignee: SHPP GLOBAL TECHNOLOGIES B.V.
    Inventors: Simon Padmanabhan, Sivakumar Periyasamy, Gregory L. Hemmer, Robert John Werling, Ravi Gautam
  • Patent number: 11905264
    Abstract: A N?-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-4-nitrobenzimidamide compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: October 13, 2023
    Date of Patent: February 20, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Mai Mostafa Khalaf Ali, Hany Mohamed Abd El-Lateef Ahmed, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • Patent number: 11897849
    Abstract: A N?-(2-(5-phenyl-1,3,4-oxadiazol-2-ylthio)acetoxy)-1-naphthimidamide compound, its synthesis, and its use as an anti-microbial agent.
    Type: Grant
    Filed: October 9, 2023
    Date of Patent: February 13, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • Patent number: 11897858
    Abstract: The present disclosure relates to a new salt of escitalopram and its solid state forms, processes for the preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Grant
    Filed: July 17, 2022
    Date of Patent: February 13, 2024
    Inventor: Mark Hasleton
  • Patent number: 11897892
    Abstract: The present disclosure relates generally to certain tricyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.
    Type: Grant
    Filed: February 3, 2023
    Date of Patent: February 13, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Hang Chu, Ana Z. Gonzalez Buenrostro, Hongyan Guo, Xiaochun Han, Anna E. Hurtley, Lan Jiang, Jiayao Li, David W. Lin, Michael L. Mitchell, Devan Naduthambi, Gregg M. Schwarzwalder, Suzanne M. Szewczyk, Matthew J. Von Bargen, Qiaoyin Wu, Hong Yang, Jennifer R. Zhang
  • Patent number: 11897872
    Abstract: Azaspirocycle compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions: wherein X, R1, R2a, R2b, R3, m, n, o, and p are defined herein.
    Type: Grant
    Filed: October 31, 2022
    Date of Patent: February 13, 2024
    Assignee: Janssen Pharmaceutica NV
    Inventors: Jesus Alcazar, Michael K. Ameriks, Cynthia B. Berry, Pablo Garcia-Reynaga, Andrew V. Samant, J. A. Vega-Ramiro
  • Patent number: 11897883
    Abstract: Novel pyrrolo[3,2-c][1,6]naphthyridine-2-carboxylic acid compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The pyrrolo[3,2-c][1,6]naphthyridine-2-carboxylic acid compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.
    Type: Grant
    Filed: September 1, 2023
    Date of Patent: February 13, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Michelyne Haroun, Christophe Tratrat
  • Patent number: 11891405
    Abstract: The present application belongs to the field of pharmaceutical chemistry, and relates to a furo[3,4-b]pyrrole-containing BTK inhibitor, and in particular, to a compound of formula (I), a stereisomer or pharmacologically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition containing the compound, and use thereof in treating BTK-related diseases.
    Type: Grant
    Filed: September 12, 2019
    Date of Patent: February 6, 2024
    Assignee: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Yinsheng Zhang, Hongjiang Xu, Jing Ren, Qinglin Wang, Zheyang Wu, Chao Jin, Wei Shi, Xiaojin Wang, Xiangyi He, Xiayun Chang, Jie Wang, Tianxiao Zhao
  • Patent number: 11891385
    Abstract: A 1-cyclopropyl-7-(4-((5-(4-chlorobenzylideneamino)-2-thioxo-1,3,4-thiadiazol-3(2H)-yl)methyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid compound, its synthesis, and its use as an anti-inflammation agent.
    Type: Grant
    Filed: October 5, 2023
    Date of Patent: February 6, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Mai Mostafa Khalaf Ali, Hany Mohamed Abd El-Lateef Ahmed, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • Patent number: 11882835
    Abstract: Provided are a benzimidazole compound represented by the general formula (1) {wherein R1 represents a hydrogen atom or a cyano group, R2 represents a (C1-C6) alkyl group, a (C1-C6) alkoxy (C1-C6) alkyl group, or a halo (C1-C6) alkyl group, R represents a (C1-C3) alkylene group or a halo (C1-C3) alkylene group, and m represents 0, 1, or 2}, or a salt thereof, an agricultural and horticultural insecticide comprising the compound or the salt as an active ingredient; an animal ectoparasite or endoparasite control agent comprising the compound or the salt as an active ingredient; and a method for using the insecticide or the agent.
    Type: Grant
    Filed: July 9, 2019
    Date of Patent: January 30, 2024
    Assignee: NIHON NOHYAKU CO., LTD.
    Inventors: Ikki Yonemura, Shunpei Fujie
  • Patent number: 11865110
    Abstract: Thrombin-inhibiting acylated pyrazole-pyridone compounds of formula (II) are disclosed herein, as well as pharmaceutical compositions, including tablets, that contain acylated pyrazole-pyridone compounds. These compounds are useful for the treatment and prevention of thrombin-related related diseases and disorders. Processes for making tablets containing acylated pyrazole-pyridones are also included.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: January 9, 2024
    Assignee: Verseon International Corporation
    Inventors: Kevin Michael Short, Maria de los Angeles Estiarte-Martinez, David Ben Kita, Nilantha Sudath Sirisoma
  • Patent number: 11858889
    Abstract: Disclosed are compounds that can modulate DDAH and the amount of asymmetric dimethylarginine (ADMA) in a subject. Also provided are pharmaceutical compositions comprising these compounds, as well as methods of using these compositions to treat and/or prevent diseases associated with elevated or low levels of DDAH and ADMA.
    Type: Grant
    Filed: December 30, 2021
    Date of Patent: January 2, 2024
    Assignee: THE TRUSTEES OF INDIANA UNIVERSITY
    Inventors: Jaipal Singh, Kerry Fowler
  • Patent number: 11851420
    Abstract: The present invention relates to nitro-vinyl-pyrazole compounds of formula (B) wherein ring A, RB2 and RB3 are as defined in claim 1, as well as the manufacture of such compounds and their subsequent use in the production of agrochemicals and/or pharmaceuticals.
    Type: Grant
    Filed: December 7, 2022
    Date of Patent: December 26, 2023
    Assignee: SYNGENTA CROP PROTECTION AG
    Inventors: James Alan Morris, Sally Elizabeth Russell, Sean Ng
  • Patent number: 11845710
    Abstract: The present application relates to a method for citalopram intermediate citalopram diol. The method comprises: first mixing two Grignard reagents required for a reaction; then mixing the mixed Grignard reagents with a raw material 5-cyanophthalide in a temperature-controllable micromixer to obtain a reaction solution; then subjecting the reaction solution to the reaction by means of a reactor to obtain a citalopram diol reaction solution; and then performing operations such as quenching, concentration, extraction, acidification, and crystallization to obtain a qualified product. The citalopram diol provided in the present invention has good selectivity, high yield, high safety, safety and reliability, and little sewage discharge, and is suitable for industrial production.
    Type: Grant
    Filed: December 2, 2019
    Date of Patent: December 19, 2023
    Assignees: ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD, SHANGHAI AOBO PHARMTECH, INC., LTD.
    Inventors: Chen Liu, Xing Li, Huaxiang Ye, Jicheng Zhang, Luning Huang, Anping Tao, Jianguo An, Hong Gu
  • Patent number: 11845724
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of USP30, and the treatment of USP30-mediated disorders.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: December 19, 2023
    Assignee: Vincere Biosciences, Inc.
    Inventors: Donna L. Romero, Michael Garrett Johnson, Andrew David Lee, Bahareh Behrouz, Edward Lawrence Fritzen, Jr.
  • Patent number: 11845715
    Abstract: The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.
    Type: Grant
    Filed: August 18, 2021
    Date of Patent: December 19, 2023
    Assignees: THE UNIVERSITY OF QUEENSLAND, THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN
    Inventors: Luke O'Neill, Rebecca Coll, Matthew Cooper, Avril Robertson, Kate Schroder
  • Patent number: 11839600
    Abstract: This invention addresses tetrahydro-N, N-dimethyl-2,2diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73, AV2-73, or A2-73) in a method of treatment for neurodevelopmental disorders. Particular reference is made to the treatment of autism spectrum disorder, cerebral palsy, Rett syndrome, Angelman syndrome, Williams syndrome, pervasive developmental disorder not otherwise specified (PDD-NOS), childhood disintegrative disorder, and Smith-Magenis syndrome. Additional reference is made to multiple sclerosis.
    Type: Grant
    Filed: August 17, 2022
    Date of Patent: December 12, 2023
    Assignee: Anavex Life Sciences Corp.
    Inventor: Christopher U. Missling
  • Patent number: 11834392
    Abstract: The invention relates to KDM4B inhibitors, compositions comprising an effective amount of KDM4B inhibitors and methods for treating inflammatory diseases and disorders.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: December 5, 2023
    Assignee: MUSC Foundation for Research Development
    Inventors: Patrick M. Woster, Joy E. Kirkpatrick
  • Patent number: 11833250
    Abstract: The present invention concerns tablet formulations of fosfomycin trometamol, methods of manufacturing and using thereof. More specifically, it relates to an oral pharmaceutical composition in tablet form comprising or consisting of: a. fosfomycin trometamol; b. a low moisture diluent selected from the group consisting of anhydrous calcium hydrogen phosphate, anhydrous microcrystalline cellulose and combinations thereof; c. optionally, a lubricant; and d. optionally, other pharmaceutically acceptable excipients.
    Type: Grant
    Filed: February 9, 2022
    Date of Patent: December 5, 2023
    Assignee: LABIANA HEALTH, S.L.
    Inventors: Marta Prior Ortega, Ramon Francesch Ollé
  • Patent number: 11826337
    Abstract: Provided in some embodiments are titration packages, kits, and methods of treating pulmonary arterial hypertension comprising prescribing and/or administering to a patient in need thereof 2-(((1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, via a titration scheme that comprises the up-titration of Compound 1, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, over a period of no more than about nine weeks until an optimized dose is administered.
    Type: Grant
    Filed: July 12, 2022
    Date of Patent: November 28, 2023
    Assignee: ARENA PHARMACEUTICALS, INC.
    Inventor: Alan Glicklich